Status:
COMPLETED
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Lead Sponsor:
Amgen
Conditions:
Anemia
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiv...
Eligibility Criteria
Inclusion
- subjects with non-myeloid malignancies
- anemia due to cancer
- ECOG status 0 to 2
- greater than or equal to 4-month expectancy
- greater than or equal to 18 years and of legal age for informed consent
- screening hemoglobin concentration less than or equal to 11.0g/dL
- adequate serum folate and vitamin B12
- adequate renal and liver function
- written informed consent
Exclusion
- subjects currently receiving or planned to receive cytotoxic chemotherapy or myelosuppressive radiotherapy during the study or within 4 weeks before randomization
- in complete remission, as determined by the investigator
- subjects who have other diagnoses not related to the cancer which cause anemia (eg. gastrointestinal bleeding, renal disease, etc)
- documented history of pure red cell aplasia
- Known history of seizure disorder
- cardiac condition: uncontrolled angina, congestive heart failure, known ejection fraction less than 40%, or uncontrolled cardiac arrhythmia
- uncontrolled hypertension
- clinically significant systemic infection or chronic inflammatory disease present at the time of randomization
- iron deficiency
- known positive test for HIV infection
- previously suspected of or confirmed to have neutralizing antibodies to rHuEPO or darbepoetin alfa
- received rHuEPO or darbepoetin alfa therapy within 4 weeks of randomization
- less than 30 days since receipt of any investigational drug or device that is not approved by the applicable regulatory authority
- pregnant or breast feeding
- subject of reproductive potential who is not using adequate contraceptive precautions
- known hypersensitivity to mammalian-derived product or any other ingredients in the investigational product
- previously randomized into this study
- concerns for subject's compliance with the protocol procedures
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00091858
Start Date
April 1 2004
End Date
December 1 2006
Last Update
May 8 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.